Need help finding what you are looking for?
Contact Us
PUBLISHER: BCC Research | PRODUCT CODE: 1267446
PUBLISHER: BCC Research | PRODUCT CODE: 1267446
Next-Generation Cancer Diagnostics: Technologies and Global Markets
PUBLISHED:
PAGES: 166 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Highlights:
The global next-generation cancer diagnostics market reached $8.7 billion in 2022 and should reach $15 billion by 2027, with a compound annual growth rate (CAGR) of 11.5% during the forecast period of 2022-2027.
Breast segment of the global next-generation cancer diagnostics market reached $2.2 billion in 2022 and should reach $3.9 billion by 2027, with a CAGR of 11.6% during the forecast period of 2022-2027.
Urinary system segment of the global next-generation cancer diagnostics market reached $610.4 million in 2022 and should reach $1.2 billion by 2027, with a CAGR of 14.5% during the forecast period of 2022-2027.
Report Scope:
This research report analyzes leading next-generation diagnostic technologies, including next generation sequencing (NGS), polymerase chain reaction (PCR), multiplex conventional, cell or extracellular vesicle capture, and arrays/microfluidics. The report also discusses various liquid biopsy platforms and how these compare with tissue-based testing.
The report discusses several significant, large-scale research initiatives contributing to cancer diagnostic development. Key forces driving the market are discussed.
An in-depth analysis of key companies operating in the next-generation cancer diagnostic and technologies market is also included. The information also focuses on companies involved in developing products and emerging technologies.
The market for next-generation cancer diagnostics is analyzed in depth. The market is analyzed by cancer site (bladder, brain, breast, colorectal, cancer of unknown primary, gastric, gynecologic, hematologic, kidney, liver, lung, pan-cancer, pancreatic, prostate, melanoma, and thyroid), by test purpose (screening/early detection, diagnosis, monitoring, therapy guidance), by test platform (arrays/microfluidics, cell/EV capture, multiplex conventional, PCR and NGS) and by geography (North America, Europe, Asia-Pacific, and Rest of World).
The base year for market data is 2021, with historical data provided for 2020 and 2019 and forecast data provided through 2027. Historical, base year, and forecast data are provided for each market segment of the report.
Report Includes:
- 15 data tables and 80 additional tables
- An overview of the global market and technologies for next generation cancer diagnostics
- Estimation of the market size and analyses of global market trends, with data from 2021, estimates for 2022 and projections of compound annual growth rates (CAGRs) through 2027
- Highlights of the current and future market potential and quantification of next generation cancer diagnostics market based on type, application, and region
- Description of arrays and microfluidics (LOAC) technologies, multiplex conventional technologies, next generation sequencing technology and polymerase chain reaction (PCR) technology
- Analysis of underlying technological, environmental, legal/regulatory, and political trends that may influence the size and nature of the market
- Coverage of the key initiatives and programs related to the next generation cancer diagnostics market
- Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies
- Company profiles of major players within the industry, including Abbott Laboratories, Illumina Inc., Becton, Dickinson and Co., and Illumina Inc.
Product Code: BIO081D
Table of Contents
Chapter 1 Introduction
- 1.1 Study Goals and Objectives
- 1.2 Reasons for Doing This Study
- 1.3 Scope of Report
- 1.4 What's New in This Update?
- 1.5 Information Sources and Methodology
- 1.5.1 Secondary Research
- 1.5.2 Primary Research
- 1.6 Research Methodology
- 1.7 Geographic Breakdown
- 1.8 Analyst's Credentials
- 1.9 BCC Custom Research
- 1.10 Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
- 3.1 Overview
- 3.2 Next Generation Sequencing in Personalized Medicine
- 3.2.1 Cost-Effective
- 3.2.2 Samples Required
- 3.3 NGS in Clinical Oncology
- 3.3.1 Accurate Detection of Genetic Mutations
- 3.3.2 Precision Diagnostics
- 3.3.3 Tumor Genomic Profiling
- 3.4 Large-Scale Initiatives and Consortia
- 3.5 Liquid Biopsy Technologies
- 3.6 Liquid Biopsy as a Market-Driving Force
- 3.6.1 Key Trends
- 3.7 Industry
- 3.8 Diagnostics Overview
- 3.9 Arrays and Microfluidics (LOAC) Technologies
- 3.9.1 DNA Microarrays
- 3.9.2 Protein Microarrays
- 3.9.3 Microfluidics
- 3.10 Multiplex Conventional Technologies
- 3.11 Polymerase Chain Reaction (PCR) Technology
Chapter 4 Cancer Diagnostics Market
- 4.1 Forces Driving Growth
- 4.2 Cancer Markets
- 4.3 Market for Next-Generation Cancer Diagnostics by Cancer Site
- 4.3.1 Bladder Cancer
- 4.3.2 Brain Cancer
- 4.3.3 Breast Cancer
- 4.4 Market for Next-Generation Cancer Diagnostics by Purpose of Analysis
- 4.4.1 Screening/Early Detection Market
- 4.4.2 Diagnostics Market
- 4.4.3 Therapy Guidance Market
- 4.4.4 Monitoring Market
- 4.5 Market for Next-Generation Cancer Diagnostics by Test Platform
- 4.5.1 PCR Test Platform
- 4.5.2 NGS Test Platform
- 4.5.3 Array/Microfluidics Test Platform
- 4.5.4 Cells and/or EV Capture Test Platform
- 4.5.5 Multiplex Conventional Test Platform
- 4.6 Market for Test Platforms by Cancer Site
- 4.6.1 PCR Test Platform
- 4.6.2 NGS Test Platform
- 4.7 Market by Diagnostic Segment
- 4.7.1 Screening/Early Detection Market
- 4.7.2 Diagnostics Market
- 4.7.3 Monitoring Market
- 4.7.4 Therapy Guidance Market
- 4.7.5 Breast Cancer Diagnostics
- 4.7.6 Digestive Cancer Diagnostics
- 4.7.7 Respiratory and Skin Cancer Diagnostics
Chapter 5 Market Breakdown Application by Cancer Site
- 5.1 Overview
- 5.2 Bladder Cancer
- 5.3 Brain Cancer
- 5.3.1 Types of Brain Cancer
- 5.4 Breast Cancer
- 5.4.1 Risk
- 5.4.2 Breast Cancer Screening
- 5.4.3 Prognosis and Pharmacogenetics Tests
- 5.4.4 Breast Cancer MDx Platforms
- 5.4.5 Status of Next-Generation Breast Cancer Tests
- 5.4.6 Treatment
- 5.5 Gynecologic Cancers
- 5.5.1 Cervical Cancer
- 5.5.2 Ovarian Cancer
- 5.6 Colorectal Cancer
- 5.6.1 Conventional Colorectal Cancer Screening Tests
- 5.6.2 Next-Generation Colorectal Cancer Diagnostic Tests
- 5.7 Cancer Unknown Primary
- 5.8 Gastric Cancer
- 5.9 Kidney Cancer
- 5.10 Hematologic Tests: Leukemia and Myeloma
- 5.11 Liver Cancer
- 5.12 Lung Cancer
- 5.13 Hematologic Tests: Lymphomas
- 5.14 Melanoma
- 5.15 Pan-Cancer
- 5.16 Prostate Cancer
- 5.17 Thyroid Cancer
Chapter 6 Emerging Technologies
- 6.1 Overview
- 6.2 Population Sequencing Programs
- 6.3 Introduction
- 6.4 CRISPR
Chapter 7 Evaluation of the Market Based on Geographic Region
- 7.1 Overview of the Geographical Distribution of the Market
- 7.2 Overview
- 7.3 North America
- 7.4 Europe
- 7.5 Asia-Pacific
- 7.6 Rest of the World
Chapter 8 Patents
Chapter 9 Company Profiles
- ABBOTT LABORATORIES
- ABBVIE INC.
- ADVANCED CELL DIAGNOSTICS INC.
- AGILENT TECHNOLOGIES
- ARTIVION INC.
- BECTON, DICKINSON AND CO.
- BENITEC BIOPHARMA LTD.
- CALADRIUS BIOSCIENCES
- CELGENE CORP.
- COMMENCE BIO
- DEPUY SYNTHES (J&J)
- DRAGERWERK AG & CO. KGAA
- EPIC SCIENCES INC.
- GENEXINE
- GERON
- ILLUMINA INC.
- IMMUNOCELLULAR THERAPEUTICS
- INEX INNOVATIONS EXCHANGE PTE. LTD.
- INIVATA LTD.
- INTERPACE DIAGNOSTICS LLC
- INVIVOSCRIBE INC.
- MEDTRONIC PLC
- MERCK KGAA
- NOVARTIS AG
- ONCOCYTE CORP.
- ONCOMED PHARMACEUTICALS INC.
- PLURISTEM THERAPEUTICS INC.
- SILICON BIOSYSTEMS S.P.A
- SPHERE FLUIDICS LTD.
- THERMO FISHER SCIENTIFIC
- VITATEX INC.
Product Code: BIO081D
List of Tables
- Summary Table : Global Market for Next-Generation Cancer Diagnostics, by Cancer Site, Through 2027
- Table 1 : Large-Scale Initiatives: Cancer Diagnostics Industry
- Table 2 : Liquid Biopsy Biomarker Classes
- Table 3 : Key Trends in the Market for Next-Generation Cancer Diagnostics
- Table 4 : Next-Generation Cancer Diagnostics Industry Subsectors
- Table 5 : Diagnostic Market Segments
- Table 6 : Next-Generation Diagnostics: Key Analysis Platforms
- Table 7 : Analysis Platforms and Biomarker Types
- Table 8 : DNA Microarray Technologies in Cancer Diagnostics
- Table 9 : Design Features of Protein Microarray Technologies
- Table 10 : Microfluidic LOAC Types Used in Cancer Diagnostics
- Table 11 : Advanced Sequencing Technologies
- Table 12 : Illumina Next Generation Sequencing Workflow
- Table 13 : Thermo Fisher Scientific's Next-Generation Sequencing Workflow
- Table 14 : Main Ingredients of PCR Technology
- Table 15 : PCR Process
- Table 16 : Advantages of Droplet Digital PCR for Single-Cell Analysis
- Table 17 : Liquid Biopsy: Forces Driving Growth, 2020
- Table 18 : Limitations of Solid Biopsy in Cancer Applications
- Table 19 : Low-Frequency Mutation Detection
- Table 20 : Global Market for Next-Generation Cancer Diagnostics, by Cancer Site, Through 2027
- Table 21 : Global Market for Next-Generation Cancer Diagnostics, by Purpose of Analysis, Through 2027
- Table 22 : MRI and Liquid Biopsy Methods
- Table 23 : Early Detection: Tissue of Origin Approaches
- Table 24 : Global Market for Next-Generation Cancer Diagnostics, by Test Platform, Through 2027
- Table 25 : FDA-Approved or CE-Marked Tests with Epigenetic Component
- Table 26 : Global Market for PCR-Based Cancer Diagnostics, by Cancer Site, Through 2027
- Table 27 : Global Market for NGS-Based Cancer Diagnostics, by Cancer Site, Through 2027
- Table 28 : Global Market for Next-Generation Cancer Screening/Early Detection, by Cancer Site, Through 2027
- Table 29 : Global Market for Next-Generation Cancer Diagnostics, by Cancer Site, Through 2027
- Table 30 : Global Market for Next-Generation Cancer Monitoring, by Cancer Site, Through 2027
- Table 31 : Global Market for Next-Generation Cancer Monitoring, by Cancer Site, Through 2027
- Table 32 : Global Market for Breast Cancer Diagnostics, by Analysis Method, Through 2027
- Table 33 : Global Market for Digestive Cancer Diagnostics, by Analysis Method, Through 2027
- Table 34 : Global Market for Respiratory and Skin Cancer Diagnostics, by Analysis Method, Through 2027
- Table 35 : Bladder Cancer Diagnostic Tests, 2020
- Table 36 : Brain Cancer: Next-Generation Diagnostics Tests, 2020
- Table 37 : Annual Breast Cancer Treatment Decisions, U.S., by Cancer Classification
- Table 38 : Breast Cancer MDx Technology Platforms
- Table 39 : Next-Generation Breast Cancer Tests, 2020
- Table 40 : Next-Generation Human Papilloma Virus and Cervical Cancer Screening and Genotyping Tests
- Table 41 : Ovarian Cancer Early Screening Formats, 2020
- Table 42 : Ovarian Cancer: Next-Generation Diagnostics Tests, 2020
- Table 43 : CRC Screening Tests
- Table 44 : Colorectal Cancer: Next-Generation Diagnostic Tests
- Table 45 : Cancer Unknown Primary: Next-Generation Diagnostic Tests, 2020
- Table 46 : Gastric Cancer: Next-Generation Diagnostic Tests, 2020
- Table 47 : Kidney Cancer: Next-Generation Diagnostic Tests, 2020
- Table 48 : Leukemia and Myeloma: Next-Generation Diagnostic Tests, 2020
- Table 49 : Liver Cancer: Next-Generation Diagnostic Tests, 2020
- Table 50 : Five-Year Survival Rates for Non-Small Cell Lung Cancer
- Table 51 : Lung Cancer: Next-Generation Diagnostic Tests, 2020
- Table 52 : Lymphoma: Next-Generation Diagnostic Tests, 2020
- Table 53 : Melanoma: Next-Generation Diagnostic Tests, 2021
- Table 54 : Pan-Cancer: Next-Generation Diagnostic Tests, 2020
- Table 55 : Prostate Cancer Next-Generation Diagnostic Tests
- Table 56 : Thyroid Cancer: Next-Generation Diagnostics Tests, 2020
- Table 57 : R&D: Next-Generation Cancer Diagnostics
- Table 58 : Population Sequencing Projects
- Table 59 : Global Market for Next-Generation Cancer Diagnostics, by Region, Through 2027
- Table 60 : Select Patent Applications Filed on Next-Generation Cancer Diagnostics Technologies
- Table 61 : Abbott Laboratories: Product Portfolio
- Table 62 : Abbott Laboratories: Developments 2020-2022
- Table 63 : AbbVie: Oncology Pharmaceutical Products Portfolio
- Table 64 : AbbVie: Marketed Products
- Table 65 : AbbVie: Key Developments, 2020-2021
- Table 66 : Allergan plc: Marketed Products
- Table 67 : Advanced Cell Diagnostics: Product Portfolio
- Table 68 : Agilent Technologies: Developments, 2019-2022
- Table 69 : Artivion Inc.: Product Portfolio
- Table 70 : Artivion Inc.: Developments, 2020
- Table 71 : Becton, Dickinson and Co.: Company Financials, 2021
- Table 72 : Becton, Dickinson and Co.: Product Portfolio
- Table 73 : Becton, Dickinson and Co.: Developments, 2017-2022
- Table 74 : Benitec Biopharma: Product Portfolio
- Table 75 : Caladrius Biosciences: Product Portfolio
- Table 76 : Celgene Corp.: Product Portfolio
- Table 77 : Commence Bio: Product Portfolio
- Table 78 : DePuy Synthes: Product Portfolio
- Table 79 : DePuy Synthes: Developments, 2019-2022
- Table 80 : Drager: Product Portfolio
- Table 81 : Epic Sciences: Product Portfolio
- Table 82 : Genexine: Product Portfolio
- Table 83 : Geron: Product Portfolio
- Table 84 : ImmunoCellular Therapeutics: Product Portfolio
- Table 85 : Medtronic plc: Developments, 2019-2022
- Table 86 : Novartis: Developments, 2019 and 2020
- Table 87 : OncoCyte: Product Portfolio
- Table 88 : OncoMed: Product Portfolio
- Table 89 : Pluristem Therapeutics: Product Portfolio
- Table 90 : Silicon Biosystems: Product Portfolio
- Table 91 : Sphere Fluidics: Product Portfolio
- Table 92 : Thermo Fisher Scientific: Product Portfolio
- Table 93 : Thermo Fisher Scientific: Developments, 2019-2022
- Table 94 : Vitatex: Product Portfolio
List of Figures
- Summary Figure : Global Market for Next-Generation Cancer Diagnostics, by Cancer Site, 2019-2027
- Figure 1 : Distribution of Cases by Stage at Diagnosis: Female Breast Cancer, 2021
- Figure 2 : Global Incidence and Prevalence of Cancer Cases, by Cancer Site, 2022
- Figure 3 : Snapshot of Next-Generation Cancer Diagnostics Technologies, by Region
- Figure 4 : Global Market Shares of Next-Generation Cancer Diagnostics Technologies, by Region, 2027
- Figure 5 : Becton, Dickinson and Co.: Revenue Share, by Business Segment, 2021
- Figure 6 : Illumina Inc.: Annual Revenue, 2018-2021
- Figure 7 : Illumina Inc.: Revenue Share, by Region/Country, 2021
- Figure 8 : Illumina Inc.: Revenue Share, by Product Segment, 2021
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.